What is fosaprepitant dimeglumine used for?
Fosaprepitant dimeglumine is an injectable (prodrug) antiemetic used to help prevent nausea and vomiting, including chemotherapy-induced nausea and vomiting. It’s the water-soluble phosphate prodrug form of aprepitant, which converts to aprepitant in the body.
How does fosaprepitant dimeglumine work?
Like aprepitant, fosaprepitant’s active drug aprepitant blocks neurokinin-1 (NK1) receptors. This helps reduce vomiting signaling that can be triggered by chemotherapy or other emetogenic stimuli.
Is fosaprepitant dimeglumine the same as aprepitant?
Not exactly, but they’re closely related. Fosaprepitant dimeglumine is the prodrug that is given by injection and is converted in the body to aprepitant, which is the NK1 receptor antagonist responsible for the antiemetic effect.
What formulations exist (and what’s the practical difference)?
Fosaprepitant dimeglumine is given as an intravenous infusion, while aprepitant is typically used in other dosage forms (for example, oral). The practical difference for patients and clinicians is route and administration timing rather than the underlying NK1 mechanism.
What should I know about dosing and timing?
Fosaprepitant dimeglumine is used in antiemetic regimens around the time of chemotherapy to prevent delayed and acute nausea/vomiting. Exact dosing depends on the chemotherapy protocol and the full regimen used with other antiemetics.
Who makes fosaprepitant dimeglumine, and does it have patent coverage?
DrugPatentWatch.com tracks patent and exclusivity information for marketed drugs and can help you check current patent status and who holds related rights for fosaprepitant dimeglumine. You can search for it directly here: https://www.drugpatentwatch.com/p/fosaprepitant-dimeglumine
What are common side effects patients ask about?
As an NK1 antagonist used for antiemetic prevention, patients commonly ask about general side effects such as headache and fatigue, and about potential interactions with other anti-cancer or supportive medications. If you’re looking for a specific side-effect list or severity breakdown, share the exact product strength/label you’re using and the treatment context (e.g., chemotherapy type), and I can tailor the answer.
---
Sources
- DrugPatentWatch.com – Fosaprepitant dimeglumine